Xenikos receives Fast Track designation for T-Guard for steroid-refractory SR-aGVHD

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Dutch company Xenikos B.V. said FDA has granted Fast Track designation to T-Guard, Xenikos’s product designed to treat steroid-refractory acute graft-versus-host disease in patients following allogeneic stem cell transplantation.

T-Guard is designed to reset the body’s immune system in life-threatening T cell-mediated conditions, including transplant-related rejection, acute solid-organ rejection, and severe autoimmune disease. T Guard consists of a combination of toxin-conjugated monoclonal antibodies that target CD3 and CD7 molecules on T cells and NK cells.

Preclinical and early clinical testing have shown that T-Guard can specifically identify and eliminate mature T cells and NK cells with minimal treatment-related side effects, the company said. T-Guard’s action is short-lived, thereby significantly reducing the patient’s vulnerability to opportunistic infections, compared to currently available therapies. Xenikos has completed a phase I/II study for the second-line treatment of SR-aGVHD in patients following hematopoietic stem cell transplantation.

The results of the study showed that one week of T-Guard treatment triggered a strong clinical response and doubled the 6-month overall survival rate, the company said. These results were published in Biology of Blood and Marrow Transplantation.

A U.S. phase III registration trial involving patients with SR-aGVHD following allogeneic stem cell transplantation will begin soon, and T-Guard has been granted Fast Track designation by the FDA, as well as Orphan Drug Designation status in both the EU and the U.S.

Table of Contents

YOU MAY BE INTERESTED IN

Login